Frequency Limitations: Current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.
ICD-9 Codes are associated with CPT code 82523 in this policy.
| 242.00 | Toxic diffuse goiter without thyrotoxic crisis or storm |
| 242.01 | Toxic diffuse goiter with thyrotoxic crisis or storm |
| 242.10 | Toxic uninodular goiter without thyrotoxic crisis or storm |
| 242.11 | Toxic uninodular goiter with thyrotoxic crisis or storm |
| 242.20 | Toxic multinodular goiter without thyrotoxic crisis or storm |
| 242.21 | Toxic multinodular goiter with thyrotoxic crisis or storm |
| 242.30 | Toxic nodular goiter, unspecified, without thyrotoxic crisis or storm |
| 242.31 | Toxic nodular goiter, unspecified, with thyrotoxic crisis or storm |
| 242.40 | Thyrotoxicosis from ectopic thyroid nodule without thyrotoxic crisis or storm |
| 242.41 | Thyrotoxicosis from ectopic thyroid nodule with thyrotoxic crisis or storm |
No comments:
Post a Comment